Muscle relaxants linked with increased risk of breathing problems after surgery

Muscle relaxants given to millions of patients during general anaesthesia are associated with an increased risk of serious breathing problems after surgery, finds a study published in BMJ today.

The results also suggest that giving drugs to reverse the muscle relaxants after surgery may increase the risk further.

But an accompanying editorial argues that, in , is an extremely safe procedure and it would be a mistake to change clinical practice on the basis of this one study, however large and well executed.

Known as intermediate acting neuromuscular blocking agents, these drugs work by temporarily blocking to muscles. They decrease the need for deep anaesthesia allowing faster recovery after surgery.

When they were first introduced 70 years ago, these blocking agents revolutionised surgical care, but in the 1950s, concerns were raised that they could linger in the body after surgery, causing partial paralysis of the muscles needed for breathing, and putting patients at risk of respiratory complications.

As a result, anaesthetists are now advised to carefully measure the effects of these drugs throughout surgery and to give a drug to reverse the effects at the end of surgery. Subjective is most often used by the without any being made, however.

To address these concerns, an international team of researchers compared outcomes for 18,579 patients who received at least one intermediate acting neuromuscular blocking agent during surgery with the same number of patients who did not.

They found that , such as deteriorating (desaturation) and the need for re- after surgery (a tube inserted into the throat and airway to aid breathing) were more common if a muscle relaxant and a reversal agent had been given, particularly for shorter operations.

Although unusual, re-intubation after surgery often requires admission to an intensive care unit and help with breathing (mechanical ventilation), which is expensive and translates into a higher (but still very low) risk of dying in hospital, explain the authors.

Subjective monitoring during surgery did not significantly modify the risk.

The authors point out that they did not assess the effects of measuring muscle response during surgery in their trial, which may explain some of their findings. But they, like many other experts, believe that subjective monitoring should be replaced by specific measurements throughout an operation. This would give doctors real (objective) numbers to help them compare patient outcomes against a standard model of care.

However, they say their results suggest that neuromuscular blocking agents may be an independent risk factor for severe respiratory events in the first few days after surgery. "Strategies to prevent residual postoperative neuromuscular blockade should be revisited," they conclude.

In an accompanying editorial, Jennifer Hunter, Emeritus Professor of Anaesthesia at the University of Liverpool, says the study is timely, but she expresses concern that, in light of current available evidence, "it would seem wise to continue to use quantitative neuromuscular monitoring, intermediate acting neuromuscular blocking agents, and a reversal agent unless full recovery of neuromuscular function has been adequately demonstrated."

More information: Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study, BMJ, 2012.

Editorial: Antagonising neuromuscular block at the end of surgery, BMJ, 2012.

add to favorites email to friend print save as pdf

Related Stories

Anaesthetic linked to learning problems in children

Aug 28, 2012

(Medical Xpress)—Children who are given anaesthetic before the age of three may have an increased risk of developing learning difficulties, according to a new study involving researchers at The University of Western Australia.

InteguSeal does not reduce scoliosis surgery infections

Jul 26, 2012

(HealthDay) -- Preoperative cyanoacrylate sealant (InteguSeal) application does not reduce the risk of surgical site infection for patients undergoing scoliosis surgery, according to a study published online ...

Recommended for you

Mirabegron for overactive bladder: Added benefit not proven

5 hours ago

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Novartis Japan admits concealing drug side effects

Sep 01, 2014

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities.

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

User comments